AMPK Activators as Novel Therapeutics for Type 2 Diabetes

Author(s): Li-Fang Yu, Bei-Ying Qiu, Fa-Jun Nan, Jia Li

Journal Name: Current Topics in Medicinal Chemistry

Volume 10 , Issue 4 , 2010

Become EABM
Become Reviewer
Call for Editor


AMPK is a potential target of metabolic diseases including obesity and type 2 diabetes. The activation of AMPK can lead to an increase of glucose uptake into muscle, decreased gluconeogenesis in liver, increased fatty acid oxidation in muscle and liver, decreased fatty acid synthesis in liver and adipose tissue, and increase mitochondrial biogenesis. Until now, many efforts from industrial and academia have been focused on searching novel agents that activate AMPK directly or indirectly. This review will discuss recent advances in the search for novel therapeutic agents that mediate their activity via AMPK activation.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Page: [397 - 410]
Pages: 14
DOI: 10.2174/156802610790980611
Price: $65

Article Metrics

PDF: 39